World’s leading biobanks join a global network to advance personalized healthcare research
![](/46/pdcnewsitem/08/29/19/network-3537401_1920%20(1).jpg)
The platform enables collaboration between pharmaceutical institutions, healthcare and academic researchers to generate valuable insights and advance medical research.
BC Platforms, the provider of a powerful data and technology platform for personalized healthcare, has added three new leading biobanks to its Global Data Partner Network, BCRQUEST.com: Generation Scotland (UK), Bialystok Biobank (Poland) and Biobank Graz (Austria).
The BCRQUEST.com platform enables researchers to efficiently access harmonized data while strictly adhering to global and local data privacy and security regulations.
The platform and its supporting framework facilitate collaboration between pharmaceutical institutions, healthcare and academic researchers to generate valuable insights and advance medical research.
The addition of these three new, high-quality biobanks brings the BCRQUEST.com network to almost 3.5 million consented patient healthcare records from nearly 10 countries in North America and Europe.
Bialystok Biobank focuses on clinical samples for cancer and specifically on new biomarkers for early diagnosis, as well as personalized therapy of cancer-based on genetic-molecular disorders.
Biobank Graz is one of the biggest biobanks in the world with 20 million tissue, blood and DNA samples from more than 1.2 million patients.
Generation Scotland is a population-based cohort designed to study the genetic and environmental determinants of health.
Dr Christian Gülly, COO, Biobank Graz, Medical University of Graz, Austria, commented: “We are excited to be collaborating with BC Platforms to securely share our data for the benefit of patients without compromising any privacy issues. We have been impressed by the BCRQUEST.com platform and its ability to analyse, integrate and share data in a secure manner and in line with the European General Data Protection Regulation (GDPR) to support researchers in developing personalized medicines.”
Given BC Platforms' strong focus on genetic and clinical data, Tero Silvola, CEO of BC Platforms described their growing network as a "unique" and "invaluable asset" for researchers and industry. Speaking of the new addition, he said: "This will progress the development of personalized healthcare for the benefit of patients, healthcare systems and research.”
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance